Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Group of Professor Kristijan Ramadan has published an original scientific article in Nature Communications today. The article has the first report of a new autophagy receptor TEX264, which may be involved in tumours developing drug resistance.

 

Autophagy (self-eating) is a critical cell process that allows cells to degrade and cycle damaged cell components.  In this case, TEX264 is key to identifying and recycling DNA with a permanent chemical link to a protein.

Covalent attachment of proteins to DNA is a constant problem.  Unless cells can clear their DNA of attached proteins they would die, so we knew they could do this, we just didn’t know how.

 Kristijan Ramadan’s group has uncovered how cells handle one example of this, the formation of a permanent link between DNA and a protein called Topoisomerase 1 to give a Topoisomerase 1 -cleavage complex (Top1-ccs).  Topoisomerase 1 (Top-1) is usually involved in unwinding DNA strands so that they may be easily copied, but if Top-1 gets permanently linked to DNA copying would get stuck and the cell would suffer further DNA damage. 

Specialised DNA repair machinery composed of the p97 ATPase, SPRTN protease and an autophagy receptor TEX264, tackles the linked protein-DNA.   Inactivation of the p97-SPRTN-TEX264 complex leads to accumulation of Top1-ccs and genomic instability. Pathological accumulation of Top1-ccs is linked to neurodegeneration and cancer.

The discovery of TEX264 and role it plays in resolving problems associated with covalent linking of proteins to DNA is important for cancer therapy, as Topoisomerase 1 inhibitors are one of the commonly used chemotherapeutics and they kill cancer cells by accumulation of Top1-ccs. Kristijan Ramadan’s report could be vital in treating tumours which have become resistant to Topoisomerase 1 inhibitors.

 

The full publication can be read here

Similar stories

New funding for development of world's first lung cancer vaccine

Oxford and UCL researchers seeking to create the world’s first vaccine to prevent lung cancer in people at high risk of the disease have been granted up to £1.7 million from Cancer Research UK and the CRIS Cancer Foundation.

Researchers develop easy-to-deploy federated learning system that safeguards patient data

The technique, which builds on recent advances in decentralised machine learning, uses inexpensive pre-programmed micro-computers, making it easy to deploy in hospitals and cheap to scale up.

Festive Science Image Competition Winners

Winners of the Medical Research Foundation's second Festive Science Image Competition, run in partnership with the Medical Research Council (MRC), have been announced today.

Robert Watson Awarded ACP McElwain and Presidents Prize

Dr Robert Watson has won one of three McElwain and President's Prizes from the Association of Cancer Physicians for his DPhil work undertaken with Professor Ben Fairfax.